Nodexus Inc. Company

Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.
Technology: mHealth
Industry: P4 Medicine
Headquarters: United Kingdom
Founded Date: 2014
Employees Number: 1-10
Funding Status: Seed
Investors Number: 3
Estimated Revenue: Less than $1M
Last Funding Type: Seed

Visit Website
info@nodexus.com
https://twitter.com/NodexusInc
Register and Claim Ownership